Sign in
CompletedNo phase

Effect of Continuous Glucose Monitoring on Hypoglycemia in Adults With Pancreatogenic Diabetes

Key facts

Who runs it
Aalborg University Hospital
Where
Denmark1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
30 people enrolled
Started
8 Sept 2022
Ended
5 Jun 2024
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Continuous glucose monitoring
Record updated
4 October 2024

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Signed informed consent before any study specific procedures
  • Able to read and understand Danish
  • Male or female age ≥ 18 ≤ 85 years
  • A definitive diagnosis of chronic pancreatitis based on the M-ANNHEIM criteria
  • A diagnosis of insulin treated pancreatogenic diabetes based on the World Health Organization criteria for diabetes (HbA1c ≥6.5 % (48 mmol/mol) and/or fasting plasma glucose ≥126 mg/dl (7.0 mmol/l)) >3 months after diagnosis of pancreatitis

Who cannot take part

  • Attack of acute on chronic pancreatitis requiring admission within four weeks prior to inclusion
  • Use of glucocorticoid medications within four weeks prior to inclusion, with the exception of inhaled glucocorticoids in the treatment of chronic pulmonary diseases
  • Prior pancreatic surgery (including total pancreatectomy, pancreaticoduodenectomy, distal pancreatectomy, pancreaticojejunostomy, enucleation, or Frey procedure)
  • Prior gastric surgery or vagotomy
  • Known or suspected abdominal cancer (incl. intestine, pancreas, and the hepato-biliary system)
  • Presence of autoimmune antibodies suggestive of type 1 diabetes
  • Autoimmune pancreatitis
  • Severe pre-existing comorbidities (assessed by investigator upon inclusion)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will investigate the effect of continuous glucose monitoring (CGM) (compared to self-monitoring) on hypoglycemia and glycemic control in patients with insulin-treated pancreatogenic diabetes.

The 2 groups in the trial

  • Continuous glucose monitoringTreatment being tested

    Participants will monitor their glucose levels using CGM with access to interstitial glucose levels continuously throughout the day. Each study period is preceded by 20 days of masked CGM assessment.

  • Self-monitoring of blood glucoseNo study treatment, for comparison

    Participants will monitor their blood glucose levels using a glucometer and a capillary blood sample from finger-pricking. Participants will in addition use masked CGM for the last 20 days of the study period to monitor glucose levels for comparison. Each study period is preceded by 20 days of masked CGM assessment.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
4 October 2024